Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07461701

Study of 15% Versus 30% Velocity Loss Thresholds During Bodyweight Squats and Their Effects on Strength and Endurance in Young Women

Effect of 15% Versus 30% Intra-Set Velocity Loss Thresholds During Bodyweight Squats on Lower-Limb Strength and Muscular Endurance in Non-Athletic Young Female Adults.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
52 (estimated)
Sponsor
University of Health Sciences Lahore · Academic / Other
Sex
Female
Age
18 Years – 25 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to learn how two different velocity loss thresholds (15% and 30%) during bodyweight squats affect strength and endurance in non-athletic young women aged 18-25 years. The main questions it aims to answer are: Does a lower velocity loss threshold (15%) during bodyweight squats improve lower-limb strength? Does a higher velocity loss threshold (30%) during bodyweight squats improve muscular endurance? Researchers will compare the two groups (15% vs. 30% velocity loss) to see if one approach works better for strength and endurance. Participants will: Perform bodyweight squats three times per week for six weeks. Be randomly assigned to either the 15% or 30% velocity loss group. Complete strength and endurance tests before and after the program

Detailed description

This randomized controlled trial will examine the effects of two intra-set velocity loss (VL) thresholds, 15% and 30%, during bodyweight squats on lower-limb strength and muscular endurance in non-athletic young female adults. Velocity-based resistance training (VBRT) is increasingly used to regulate training intensity and volume, but most existing evidence comes from trained male athletes performing loaded exercises. There is limited research on accessible, equipment-free protocols such as bodyweight squats, particularly in underrepresented populations such as non-athletic young women. A total of 52 female university students aged 18-25 years will be recruited using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). Participants will be randomly assigned to either the 15% Velocity Loss group or the 30% Velocity Loss group, with 26 participants per group. Both groups will perform bodyweight squat sessions three times per week for six weeks. Outcomes will be assessed before and after the intervention by a blinded assessor. Primary outcomes include lower-limb strength and muscular endurance. Data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 27, with statistical significance set at p \< 0.05. The study aims to determine whether a lower Velocity Loss threshold (15%) produces comparable improvements in strength and endurance to a higher Velocity Loss threshold (30%) when using bodyweight squats. Findings will provide evidence to guide physiotherapists, exercise professionals, and health educators in designing safe, accessible, and effective training programs for non-athletic young women.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBody-weight squat training (15% velocity loss threshold)Participants will perform supervised body-weight squat training using an intra-set velocity loss threshold of 15%. Velocity loss will be monitored using standardized metronome cadence as a proxy for movement velocity. Training frequency, volume, and progression will be consistent across groups except for the velocity loss threshold.
BEHAVIORALBody-weight squat training (30% velocity loss threshold)Participants will perform supervised body-weight squat training using an intra-set velocity loss threshold of 30%. Velocity loss will be monitored using standardized metronome cadence as a proxy for movement velocity. Training frequency, volume, and progression will be consistent across groups except for the velocity loss threshold.

Timeline

Start date
2026-02-22
Primary completion
2026-04-05
Completion
2026-04-19
First posted
2026-03-10
Last updated
2026-03-10

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07461701. Inclusion in this directory is not an endorsement.